16 news items
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
REGN
16 Jun 24
ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN
31 May 24
Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN
31 May 24
obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
REGN
31 May 24
and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability
rwct8roffqmplizut07oczapxz cx9y3gf6o2xjuwldwotv7dfg
REGN
31 May 24
Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical
64z7smjf5kmb3cb 4c32a1a36n619
REGN
23 May 24
and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability
e645gqyyr9l3ew9ii20r
REGN
20 May 24
Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical
i7t09gf29f9n9e24v9leltpxy97vwiv1nal07aiz2krace
REGN
20 May 24
and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy
uz7rru6etw8wzwzk0jvsvh1l11hu3fqms
REGN
13 May 24
and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business
e0mpvj 8tyin6jo7isrz87el9jyct0rzg379ibpc5c00q1exytqmoa9g9jul
REGN
8 May 24
ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight
9yviksy8ip77zsav2utbbzqgzqvjxiglmcxl2lcftgxdwaf24cdhh
REGN
2 May 24
to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight
gcbjoitgohabi60hhp2c6x7a lfwnc
REGN
29 Apr 24
to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's
2y4979ccod5jqn5meph3sroj07llkeja4lgxjp
REGN
22 Apr 24
Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research
70xryb4kzjwz783806kixrrx0278yx5wruhqz5q659qw6lyskp53c
REGN
7 Apr 24
and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs
kpblc 08j3cmi9thgb3dj8sgj1hace9ild1mbmdpfy1c4t9l33spxus
REGN
25 Mar 24
and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business
- Prev
- 1
- Next